Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicyclol SCHEMBL29380248 | 1.00 | TARBP2 (0.43) | TARBP2CYP3A4ALOX15KDM4EALDH1A1 | |
| Bifendate SCHEMBL896166 | 0.92 | TARBP2 (0.48) | TARBP2CYP3A4ALOX15KDM4EALDH1A1 | |
| Bifendate SCHEMBL30788692 | 0.92 | TARBP2 (0.48) | TARBP2CYP3A4ALOX15KDM4EALDH1A1 | |
| Bifendate SCHEMBL29516235 | 0.92 | TARBP2 (0.48) | TARBP2CYP3A4ALOX15KDM4EALDH1A1 | |
| SCHEMBL23438996 | 0.90 | TARBP2 (0.41) | TARBP2CYP3A4ALOX15KDM4EALDH1A1 | |
| SCHEMBL21600700 | 0.88 | TARBP2 (0.41) | TARBP2CYP3A4ALOX15KDM4EALDH1A1 | |
| SCHEMBL9602401 | 0.88 | HSD17B10 (0.40) | CYP3A4ALOX15ALDH1A1HSD17B10 | |
| SCHEMBL9603034 | 0.88 | CYP3A4 (0.43) | CYP3A4ALOX15KDM4EALDH1A1MEN1 | |
| SCHEMBL23438995 | 0.87 | PDCD1 (0.40) | TARBP2CYP3A4ALOX15KDM4EMEN1 | |
| SCHEMBL9602591 | 0.86 | TARBP2 (0.37) | TARBP2KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2048574-A | — | — | None | — | — | JP | disclosed |
| JP-3153680-A | — | — | None | — | — | JP | disclosed |
| JP-63192771-A | — | — | None | — | — | JP | disclosed |
| US-20230158161-A1 | DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | CELLA THERAPEUTICS, LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230002343-A1 | LEFT-HANDED BICYCLIC MORPHOLINE AND SALT THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11147855-B2 | Methods for treating glaucoma or ocular hypertension comprising delivery of prostaglandins to the vitreous humour | CELLA THERAPEUTICS, LLC (US) | 2021-10-19 | — | — | US | disclosed |
| WO-2021103749-A1 | LEFT-HANDED BICYCLIC MORPHOLINE AND SALT THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATION | 中国医学科学院药物研究所 | 2021-06-03 | — | — | WO | disclosed |
| US-20210121534-A1 | SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR NEUROTROPHIC AGENT FOR USE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | CELLA THERAPEUTICS, LLC | 2021-04-29 | — | — | US | disclosed |
| US-20210100907-A1 | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR | CELLA THERAPEUTICS, LLC | 2021-04-08 | — | — | US | disclosed |
| US-20200108117-A1 | DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | CELLA THERAPEUTICS, LLC | 2020-04-09 | — | — | US | disclosed |
| EP-0353358-B1 | BIS(METHYLENEDIOXY)BIPHENYL COMPOUNDS | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1993-08-18 | — | — | EP | disclosed |
| JP-H03153680-A | BIPHENYL COMPOUND AND PROCESS FOR PRODUCTION OF THE SAME | ZHONGGUO YIXUEKEXUEYUAN YAOWO YANJIUSUO | 1991-07-01 | — | — | JP | disclosed |
| JP-H0248574-A | BIS(METHYLENEDIOXY)BIPHENYL COMPOUND | CHUNGUO IISHE KUUSHUEYUANYAOU IENJUSUO | 1990-02-19 | — | — | JP | disclosed |
| EP-0353358-A1 | Bis(methylenedioxy)biphenyl compounds | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1990-02-07 | — | — | EP | disclosed |
| US-4868207-A | Bis (methylenedioxy) biphenyl compounds useful for the treatment of liver diseases | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1989-09-19 | — | — | US | disclosed |
| JP-S63192771-A | 2,3,2',3'-BIS(METHYLENEDIOXY)BIPHENYL COMPOUND, PRODUCTION THEREOF AND REMEDY FOR LIVER DISEASE CONTAINING SAID COMPOUND | ISUKURA SANGYO KK | 1988-08-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210100907-A1 | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR | NGFR, TNFRSF1A, TNFSF10 | TARBP2 2224/4885CYP3A4 4701/4885ALOX15 1245/4885 |
| US-20230158161-A1 | DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | NPR1, NPR3, NTSR2 | TARBP2 2930/4885CYP3A4 4709/4885ALOX15 2617/4885 |
| US-20230002343-A1 | LEFT-HANDED BICYCLIC MORPHOLINE AND SALT THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | SLC10A1, CYP7B1, ALG3 | TARBP2 3291/4885CYP3A4 144/4885ALOX15 594/4885 |
| US-20210121534-A1 | SUSTAINED-RELEASE DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A CNP COMPOUND, AN NPR-B COMPOUND, A TIE-2 AGONIST, OR NEUROTROPHIC AGENT FOR USE FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | NPR1, NGFR, NTSR2 | TARBP2 3500/4885CYP3A4 4714/4885ALOX15 2355/4885 |
| US-20200108117-A1 | DRUG DELIVERY SYSTEMS COMPRISING AN INTRAOCULAR PRESSURE LOWERING AGENT, A NEUROTROPHIC AGENT, A C-TYPE NATRIURETIC PEPTIDE, A NATRIURETIC PEPTIDE RECEPTOR-B, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR OR A FAS-LIGAND INHIBITOR FOR TREATING GLAUCOMA OR OCULAR HYPERTENSION | NPR1, NPR3, NTSR2 | TARBP2 2930/4885CYP3A4 4709/4885ALOX15 2617/4885 |
| US-11147855-B2 | Methods for treating glaucoma or ocular hypertension comprising delivery of prostaglandins to the vitreous humour | NPR1, PGF, NPR3 | TARBP2 4175/4885CYP3A4 4686/4885ALOX15 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.